LGVN Longeveron Inc - Ordinary Shares - Class A

$LGVN Against my better better judgment. I added more today and got my avg to 1.63/share. Officially on TILT now. Don't recommend you follow lmao

$LGVN Against my better judgement, just added more shares at 1.41 to get my avg down to 1.79/share.

$LGVN Well back to $1s didn't take long. Asset sale or merger isn't going to save the stock price. Seen this movie way too many times in biotech.

$LGVN this is now trading at a market cap that is valued less than the NASDAQ listing alone. The way forward for this company has to be asset sale and reverse merger or reverse merger w/ CVRs. Either option should cause stock to rise from these depressed levels.

$LGVN For clarification on $LGVN: The insider transactions shown at $2.59 were not voluntary open-market sales. Shares were withheld to cover tax obligations related to RSU vesting. This may have contributed to yesterday’s selling pressure or been misinterpreted by the market. In my view, once this pressure clears, the stock could see a rebound soon.

$LGVN I’m not long but I would look for exit liquidity. The remaining longs tend to create a moment where they blow it up to get out. Look for that. NEGG RS then exit liquidity came and it went like 4.00 post split to 120 which was actually higher than my initial entry… food for thought

$LGVN A true investor is not shaken by negative voices or driven by fear and pessimism. Instead, their decisions are guided by research, knowledge, and conviction. They understand the difference between fact-based criticism and baseless fearmongering. Patience is strength, informed conviction is the foundation of success, and market volatility does not change a company’s scientific achievements.

$LGVN | Strong Science, Promising Future! 🚀 Longeveron has an experienced leadership team with connections to biotech companies acquired in multibillion-dollar deals. Its promising Alzheimer’s and aging-related frailty research has been published in prestigious scientific journals. The company also won $1 million in the XPRIZE Healthspan competition and remains eligible for a grand prize of up to $81 million. Major institutional investors, including Millennium, Logos, and Janus Henderson, have previously held stakes in LGVN. Despite the recent clinical setback, its remaining programs hold significant potential. A successful trial or strategic partnership could dramatically change the company’s valuation. The stock price may be low, but its scientific potential deserves attention! 🚀

$LGVN this could be the field that boom like all the ai stocks did. Ai could enhance this rapidly over the coming years buying this could be like buying Nvidia at 2 bucks. I’ll buy 10k shares just in case.

$LGVN Well, mgmt wasn't lying about having enough events last cc. 31 MACE events is a lot...12 vs 19...could become a much different story with 9 vs 22 events...altho what's confusing is some babies account for multiple MACE events...however might still not matter with REF the same between the groups - that to me is hard to understand...the phase 1 showed unchanged REF...I'm going to assume historically hlhs babies deteriorate in REF within a year after Glenn (otherwise why run the trial)...so the question is did both groups deteriorate or did both stay the same...

Latest company news, October 14, 2026: Longeveron's chief medical officer, Dr. Nataliya Agafonova, stepped down; the 8-K names no successor. More details in our $LGVN hub on our site. Not investment advice.

$LGVN It's dead, with no cash today and no p3 running, you're out. It's a different word , the free money is gone for good.